[6] Medi-Tech was the brainchild of Itzhak Bentov, a Czech-born émigré to Israel and then to the United States, who worked at the Arthur D. Little think tank in Cambridge, Massachusetts, and ran a contract research company from his rented house in Belmont, Massachusetts, a venture he founded in 1965 with a business friend, Dan Singer.

After a decade of steady growth, by chance Abele met Pete Nicholas in their neighborhood in Concord, Massachusetts.

Their partnership hinged on Nicholas' goal to build business enterprises and Abele's predilection for the vision and potential in noninvasive surgical instrumentation; they gathered backers in the Boston banking community to buy out the Cooper Labs interest and form the new corporation.

[citation needed] Less than a year later Kimray Medical Associates (later Mansfield Scientific, Inc.) was acquired, adding vena cava filters and cardiac output computers to the product line.

From 1995 through 1997, Boston Scientific increased its technology R&D and product offerings following several substantial acquisitions that included Cardiovascular Imaging Systems (intravascular ultrasound), SCIMED (cardiovascular), Vesica Medical (urology), Meadox (textile vascular prostheses), EP Technologies (cardiac ablation controllers),[12] MinTec (abdominal aortic aneurysm grafts), Symbiosis Corporation (specialty medical product manufacture), and Target Therapeutics (on neurology).

[18][19] Also, in April 2005, BSC announced it had exercised its option to acquire CryoVascular Systems, Inc., and its proprietary angioplasty device to treat atherosclerotic disease of the legs and other peripheral arteries.

[26] In December 2007, Boston Scientific announced it would sell its Fluid Management and Venous Access businesses for $425 million to Avista Capital Partners.

[28][29] Navilyst Medical was formed in February 2008 from Boston Scientific's Fluid Management and Vascular Access business units.

[30] In January 2009, Boston announced it would acquire Labcoat Limited, whose primary development was that of a development-stage drug-eluting stent – for an undisclosed sum.

[38] In June 2012, Boston Scientific officially acquired Cameron Health for a total sum of $1.3 billion, paid out incrementally as various revenue milestones were achieved.

[4] In September the company announced it would acquire BridgePoint Medical, Inc., developer of a catheter-based system to treat coronary chronic total occlusions.

[39] In October, the company acquired Rhythmia Medical, Inc., developer of mapping and navigation methods for use in cardiac catheter ablations and other electrophysiology procedures.

[54] In May 2017, the company acquired Symetis SA, a developer of minimally invasive transcatheter aortic valve implantation devices.

[82] Boston Scientific has set a standard for implementing an integrative organizational culture and states that it actively strives to further improve this by, among other things, increasing diversity among its employees – and in particular, among its managers, executives, and directors.

A New York federal court judge would hear the case without a jury to decide whether Boston Scientific should be held liable for the contract breach.

[95][96] When this was announced on 60 Minutes, Boston Scientific responded by saying the broadcast was "irresponsible and misleading,"[97] citing a 2017 Food and Drug Administration (FDA) report stating that although they found variability in the polypropylene resin, "these differences do not present new safety or effectiveness concerns.

[100] On March 23, 2021, the company agreed to pay $189 million to settle allegations that it had seriously misrepresented the risks related to the vaginal mesh.

[102] In April 2019, the FDA ordered Boston Scientific and Coloplast to remove all of their vaginal mesh products from the United States market.

[103] In 2011, Guidant, a subsidiary of Boston Scientific, was criminally convicted of a failure to report defibrillator safety problems to the FDA.

[109] In April 2024, the FDA announced a recall of Boston Scientific's device, Obsidio Embolic, which is used to stop hemorrhaging and excessive bleeding.

It has been found that when the device is paired with the aliquot technique, it can lead to bowel ischemia, which can mean longer hospitalization or death for patients.

[111] In June 2022, Boston Scientific announced that it would invest $62.5 million in a manufacturing and supply chain facility in Johns Creek, Georgia, a suburb of Atlanta.

[112][113] In 2016, Boston Scientific had acquired EndoChoice, located in Alpharetta, 10.8 mi (17.4 km) from its proposed Johns Creek facility.